Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 253

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 253
---
 of US dollars, except share and per share data and where otherwise noted) 

23.                   Financial                
      instruments and financial risk management
-----------------------------------------------
 
Financial assets and liabilities as of December 31, 2024, and 2023 are presented below.
 
Disclosure of fair value measurement of assets
 
       December 31, 2024             Financial assets at amortized cost        Financial liabilities at amortized cost    
--------------------------------------------------------------------------------------------------------------------------
                                   $                                          $                                           
Cash and cash equivalents                                         16,393                            -                     
Trade and other receivables                                        2,144                            -                     
Restricted cash equivalents        123                                                              -                     
Payables and accrued liabilities                                       -                            4,712                 
                                                                  18,660                            4,712                 

       December 31, 2023             Financial assets at amortized cost        Financial liabilities at amortized cost    
--------------------------------------------------------------------------------------------------------------------------
                                   $                                          $                                           
Cash and cash equivalents                                          6,678                            -                     
Trade and other receivables        290                                                              -                     
Restricted cash equivalents        8                                                                -                     
Payables and accrued liabilities                                       -                            1,012                 
                                                                   6,976                            1,012                 
 
The Company assessed that the fair values of cash and cash equivalents, trade receivables and other receivables, restricted cash equivalents, and payables and accrued liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.
 
Assets and liabilities, such as value added taxes, that are not contractual and that arise as a result of statutory requirements imposed by governments, do not meet the definition of financial assets or financial liabilities and are, therefore, excluded from trade and other receivables and payables and accrued liabilities.
 
Financial risk factors
 
The following provides disclosures relating to the nature and extent of the Company’s exposure to risks arising from financial instruments, including credit risk, liquidity risk and foreign exchange risk and how the Company manages those risks.
 
(a) Credit risk
 
Credit risk is the risk of an unexpected loss if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company regularly monitors credit risk exposure and takes steps to mitigate the likelihood of this exposure resulting in losses. The Company’s exposure to credit risk currently relates to the financial assets at amortized cost in the table above. The Company holds its available cash in amounts that are readily convertible to known amounts of cash and deposits its cash balances with financial institutions that have an investment grade rating of at least “P-2”